Three Decades of Drug Regulation and Legislation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Three Decades of Drug Regulation and Legislation
The US Food and Drug Administration has pursued many new initiatives since 1977. The agency began accepting abbreviated applications for generic versions of drugs, collected user fees to support drug review, launched the Critical Path Initiative to encourage innovation, and worked to harmonize its regulatory standards with those of Europe and Japan. New challenges such as AIDS and bioterrorism have affected regulatory policy in recent years. The author reviews FDA's changes in policy and philosophy during..

Pharmaceutical Technology

Despite proposals that threaten to increase the cost of drug development, regulators and manufacturers are optimistic that recent discoveries in genomic sciences and molecular biology create opportunities to develop entirely new classes of more effective and less toxic medicines, potentially at more affordable costs. Cooperative efforts to adopt new regulatory models in harmony with other nations' approaches have the potential to streamline drug development and registration, and accelerate global access to new therapies.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,

Where were you 30 years ago?
"Thirty years ago, I had just come to Washington, DC from New York, where I started my career as a business reporter for a division of Prentice-Hall. As a journalist in the nation's capital, I quickly became educated about government acronyms and Capitol Hill procedures, which provided the background necessary to become Pharmaceutical Technology's Washington editor years later."


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here